Early bird registration is open and closes 23 June 2026. Register now
Abstracts deadline Friday 24 April 2026! Submit now
Abstracts deadline EXTENDED Friday 22 May 2026! Submit now
The early bird registration deadline for APLAR 2026 has been extended until 23 June 2026 at 11:59PM — don’t miss your chance to be part of the region’s premier rheumatology event. Join us for five days of world-class speakers, interactive sessions, and unmissable networking opportunities.
Title coming soon. Objectives: Information coming soon. Agenda – Friday 30 October Chairperson: TBC
APLAR Travel Grant Invitation The Asia Pacific League of Associations for Rheumatology (APLAR) cordially invites APLAR Young Rheumatologists (AYR) to apply for the APLAR Congress Travel Grant to attend the APLAR Congress in Seoul, Republic of Korea, from 28 October – 1 November 2026. APLAR will award 50 need-based travel stipends to AYR members who have an accepted abstract for a poster, oral, or rapid-fire presentation at the APLAR Congress 2026. The grant assists AYR in covering part of the
Due to strong interest, the abstract submission deadline for APLAR 2026 has been extended to 22 May 2026, providing additional time for authors to prepare and submit their work. This extension represents the final opportunity to be considered for inclusion in the APLAR 2026 scientific program. Please note that APLAR will not offer late abstract submissions this year. We encourage all prospective authors to take advantage of the extended deadline and submit their abstracts before submissions close. Presenting at APLAR
Latest Evidence on Methotrexate and JAK Inhibitors Objectives: This session will discuss the combination therapy of JAK inhibitors with MTX and JAK inhibitors monotherapy. Agenda – Saturday 31 October Chairperson: Dr Seong-Ho Kim, Republic of Korea 1730-1825 Latest Evidence on Methotrexate and JAK Inhibitors Prof Yuko Kaneko, Japan
Polymyalgia Rheumatica: From Diagnosis to Long-Term Disease Control – Current Recommendations and Unmet Needs Objectives: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease affecting adults aged 50 years and older, characterized by bilateral pain and stiffness in the shoulder and pelvic girdles and a substantial impact on physical function and quality of life. Despite its relatively high prevalence, PMR remains a challenging condition due to heterogeneous clinical presentation, frequent diagnostic uncertainty, and a chronic or relapsing disease course in
Delegates planning to attend APLAR 2026 in Seoul, Republic of Korea, are encouraged to book their accommodation early to secure the best availability and rates. A range of official congress hotels has been carefully selected and is conveniently located close to the congress venue, offering competitive rates and flexible booking conditions. With strong early interest in APLAR 2026 and continued global demand for international travel, accommodation in Seoul is expected to fill quickly. Booking early provides peace of mind and greater choice, and
BACK IN 2026! In 2026, APLAR is continuing the rolling review of all abstract submissions. This means that you will be able to receive your submission result ahead of the submission deadline. We anticipate being able to advise your preliminary submission result within a couple weeks after completing your submission. What does this mean for you?
UP Standard Of Care in AS with Upadacitiniby Sponsored by Abbvie ObjectivesInformation coming soon. Agenda – Friday 30 October Chairperson: Dr Taehwan Kim, Republic of Korea TBC Presentation title TBC Prof Xenofon Baraliakos, Germany
Have you registered yet?
Don't miss your chance on being part of APLAR 2026 where live sessions feature the latest, best-in-class research and provide an opportunity to connect and stay apprised of the latest developments and innovations in the field.
Have you submitted your abstract yet?
Don't miss your chance on being part of APLAR 2026 where live sessions feature the latest, best-in-class research and provide an opportunity to connect and stay apprised of the latest developments and innovations in the field.
